Cardiff Oncology, Inc. (NASDAQ:CRDF) Q2 2024 Results Conference Call August 8, 2024 4:30 PM ET

Company Participants

Kiki Patel - Investor Relations, Gilmartin Group
Mark Erlander - Chief Executive Officer
Jamie Levine - Chief Financial Officer

Conference Call Participants

Andy Hsieh - William Blair
Marc Frahm - TD Cowen

Operator

Welcome to the Cardiff Oncology Second Quarter 2024 Financial Results and Business Update Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to turn the conference call over to Kiki Patel of Gilmartin Group. Please go ahead.

Kiki Patel

Thank you, operator. Joining us on the call today from Cardiff Oncology, our Chief Executive Officer, Mark Erlander, and Chief Financial Officer, Jamie Levine.

During this conference call, management will make forward-looking statements, including, without limitation, statements related to guidance, results and the timing of data readouts for onvansertib clinical trials. These forward-looking statements are based on the company's current expectations and inherently involve significant risks and uncertainties.

Our actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties.

Factors that could cause results to be different from these statements include factors the company described in the section titled Risk Factors in its annual report on Form 10-K filed with the SEC for year ended December 31, 2023. Cardiff Oncology undertakes no duty or obligation to update any forward-looking statements as a result of new information, future events or changes in its expectations.

With that, I turn the call over to Chief Executive Officer, Mark Erlander. Mark?

Mark Erlander

Thank you, Kiki, and good afternoon, everyone, and thank you for joining our business update conference call for the second quarter of 2024. These are certainly energizing times at Cardiff Oncology as we activate sites, enroll patients in our CRDF-004 trial in RAS-mutated metastatic colorectal cancer or mCRC.

The interactions we're having with the physicians and other professionals at the trial site reinforce [indiscernible] has the potential to bring a more effective therapy to this large patient population of nearly 50,000 new patients a year in the U.S. alone. Specifically, the totality of the data from our Phase Ib/II and ONSEMBLE second-line mCRC trials demonstrates onvansertib has the potential to shift the treatment paradigm for all RAS-mutated mCRC, not just subgroups to pair us.

We say this because, first, there have been no new therapies approved for these patients over the past 20 years. Second, there are no competing clinical trials for this patient population. And third, unlike prior PLK1 inhibitors, onvansertib is well tolerated when combined with chemotherapy, which also opens the door to other chemo combinations for additional cancer indications. So let's dive in.